Pasritamig

Phase 3Biologic

Johnson & Johnson

Pasritamig is one of 50 biologic programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Metastatic Castration-Resistant Prostate NeoplasmsRecruiting

Prostatic NeoplasmsRecruiting

Prostate CancerPhase 3

Active, not recruiting

Metastatic Castration-Resistant Prostate NeoplasmsPhase 3

Recruiting

Prostatic NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Pasritamig

Johnson & Johnson

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Xylocaine

MMEDRx USA, Inc.

Preclinical

—10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Prostatic Neoplasms

NCT07319871

Q2 2028

Phase 1Recruiting

Metastatic Castration-Resistant Prostate Neoplasms

NCT05818683

Q4 2028

Phase 3Recruiting

Metastatic Castration-Resistant Prostate Neoplasms

NCT07164443

Q3 2029

Phase 3Recruiting

Prostate Cancer

NCT07225946

Clinical

Trials by Indication[1]

Metastatic Castration-resistant Prostate Neoplasms2 trials

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07164443·663 enrolled

A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05818683·300 enrolled

Prostate Cancer1 trial

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07225946·800 enrolled

Prostatic Neoplasms1 trial

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07319871·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pasritamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pasritamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pasritamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Pasritamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q4 2028

Q3 2029

Trials by Indication[1]

Metastatic Castration-resistant Prostate Neoplasms2 trials

Prostate Cancer1 trial

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News